A Multicentre, Two Stage, Randomised, Double Blind Study of the Safety, Tolerability and Immunogenicity of a Human Immunodeficiency Virus (HIV) Vaccine Candidate, HIV-v.
Phase of Trial: Phase I
Latest Information Update: 08 Oct 2013
At a glance
- Drugs HIV vaccine (Primary) ; Montanide ISA-51
- Indications HIV-1 infections
- Focus Adverse reactions
- Sponsors SEEK
- 10 Jun 2017 Biomarkers information updated
- 08 Oct 2013 Phase Ib results published in Vaccine.
- 18 Jul 2011 Results will be presented at the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, according to a SEEK media release.